A glycylcycline, and the first member of this new class of tetracyclines.
A semi-synthetic derivative of minocycline.
Possesses potent activity against tetracycline-resistant gram-positive and gram-negative pathogens refractory by both efflux and ribosomal protection mechanisms.
Overcomes typical bacterial resistance to tetracyclines because of modification at position 9 of its core structure, and allows for a broader spectrum activity than traditional tetracyclines.
Binds to the bacterial 30S ribosomal unit with much greater affinity than earlier generation tetracyclines.
Has activity against gram-negative and gram-positive pathogens, anaerobes and both methicillin susceptible and methicillin resistant strains of Staphylococcus aureus.
A comparison of intravenously administered by tigecycline with imipenem and cilastatin for injection in 1,575 patients with complicated intra-abdominal infections showed equivalent efficacy.
Highly effective in patients with complicated skin and soft tissue infections, with no differences in the rate of cure in patients randomized to treatment with either tigecycline or vancomycin/aztreonam.
Nausea and vomiting are the most common adverse events.
Indicated for community acquired bacterial pneumonia caused by Streptococcus pneumoniae and Heaemophilus influenza and Legionella pneumophilia.
Does not cover Pseudomonas aeruginosa.